Tadalafil Tablet, Film Coated
Product Images NDC 43598-578

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 43598-578). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddys Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

→ Figure3new

→ Container (container)

→ Figure1 (figure1)

→ Figure2 (figure2)

→ Figure4

→ Figure5

→ Figure6

→ Image2 (image2)

→ Structure (structure)

FDA Label Image

Figure3new

This appears to be a table related to drug interactions with CYP3A substrates and specifically the drug Digoxin. The table shows different parameters including AUC (Area Under the Curve), Cmax (Maximum Concentration), and Fold Change with 90% Confidence Limits. The table suggests that there is no need for dose adjustment for Digoxin in most cases when coadministered with other drugs listed in the table. The numbers in the table seem to represent dosages of the coadministered drugs.*

FDA Label Image

Container (Container)

FDA Label Image

Figure1 (Figure1)

FDA Label Image

Figure2 (Figure2)

This text seems to be a comparison chart of different drugs and their effectiveness when co-administered with Tadalafil. It shows which drugs may inhibit or induce enzymes (CYPaA) that metabolize Tadalafil and cause a change in its effectiveness. The chart includes fold change and 90% Cl (confidence interval) for each drug and suggests whether a dose adjustment is necessary or not. However, the data seems incomplete without headings and proper formatting, and it may not be useful for medical practitioners without additional information.*

FDA Label Image